tiprankstipranks
Trending News
More News >

Mirati Therapeutics downgraded to Hold on pending buyout at Stifel

Stifel last night downgraded Mirati Therapeutics (MRTX) to Hold from Buy with a price target of $59, down from $83. The firm expects the announced takeover by Bristol Myers (BMY) to close without issue.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on MRTX:

Disclaimer & DisclosureReport an Issue

1